Expression of Recombinant Antibodies by Tumour Cells: On Road to Anti-Tumour Therapy
- 266 Downloads
Monoclonal antibodies are attractive tools for cancer therapy and have now come of age as therapeutics. Their exquisite specificity, combined with their ability to activate potent effector functions makes them an ideal tool for cancer therapy. Depending on their classes and subclasses, antibodies can activate complement and/or trigger effector functions such as Antibody-Dependent Cell Cytotoxicity (ADCC) following interactions with the receptors for the Fc region of IgG or IgA (FcγR and FcαR). Over the last decade, therapeutic antibodies have moved to the forefront of protein drug development, mostly due to the formidable capacity to engineer their immunogenicity, their affinity and their functions (Mehren et al., 2003). Therapeutic monoclonal antibodies are currently being used to target either soluble circulating molecules such as cytokines or cell surface antigens following systemic delivery. They also represent exciting tools for the targeted delivery of drugs, enzymes, and toxins at the site of the tumours. In addition, antibody-based radio-immunotherapy (RIT) should make it possible to circumvent the limitation of the treatment of solid tumours with antibodies due to the weak penetration of intact antibody molecules.
KeywordsRecombinant Antibody Chloramphenicol Acetyl Transferase Bispecific Antibody Nuclear Localisation Signal Sequence Chloramphenicol Acetyl Transferase Activity
Unable to display preview. Download preview PDF.
- Armstrong, T.D., Clements, V.K., Martin, B.K., Ting, J.P., and Ostrand-Rosenberg, S., 1997, Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 94: 6886–6891PubMedCrossRefGoogle Scholar
- Biocca, S., Neuberger, M.S., and Cattaneo, A., 1990, Expression and targeting of intracellular antibodies in mammalian cells. The EMBO J. 9: 101–108Google Scholar
- Caron de Fromentel, C., Gruel, N., Venot, C., Debussche, L., Conseiller, E., Dureuil, C., Teillaud, J.-L., Tocqué, B., and Bracco, L., Restoration of transcriptional activity of p53 mutants in human tumor cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene, 1999, 18: 551–557PubMedCrossRefGoogle Scholar
- Cochet, O., Delumeau, I., Königsberg, M., Gruel, N., Schweighoffer, F., Bracco, L., Teillaud, J.-L., and Tocqué, B., 1998a, Intracellular targeting of oncogenes: a novel approach for cancer therapy. In Intrabodies (W.A. Marasco, ed.), Landes R.G. Company, Chapman & Hall, New York, pp. 129–142Google Scholar
- Cochet, O., Kenigsberg, M., Delumeau, I., Virone-Oddos, A., Multon, M.-C., Fridman, W.H., Schweighoffer, F., Teillaud, J.-L., and Tocqué, B., 1998b, Intracellular expression of an antibody fragment neutralizing p21ras promotes tumor regression. Cancer Res. 58: 1170–1176Google Scholar
- Cochet, O., Kenigsberg, M., Delumeau, I., Duchesne, M., Schweighoffer, F., Tocqué, B., and Teillaud, J.-L., 1998c, Intracellular expression and functional properties of an anti-p21ras scFv derived from a rat hybridoma containing specific λ and irrelevant κ light chains. Mol. Immunol. 35: 1097–1110Google Scholar
- Guarini, A., Gansbacher, B., Cronin, K., Fierro, M.T., and Foa, R., 1995, IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific anti-tumor cytotoxic T-lymphocyte response. Cytokines & Mol. Ther. 1: 57–64Google Scholar
- Lecerf, J.M., Shirley, T.L., Zhu, Q., Kazantsev, A., Amersdorfer, P., Housman, D.E., Messer, A., and Huston, J.S., 2001, Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington’s disease. Proc. Natl Acad. Sci. USA 98: 4764–4769PubMedCrossRefGoogle Scholar
- Michon, J., Moutel, S., Barbet, J., Romet-Lemonne, J.-L., Deo, Y.M., Fridman, W.H., Teillaud, J.-L., 1995, In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-FcγRI bispecific antibody. Blood 86: 1124–1130PubMedGoogle Scholar
- Wang-Johanning, F., Gillespie, G.Y., Grim., J., Rancourt, C., Alvarez, R.D., Siegal, G.P., and Curiel, D.T., 1998, Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects. Cancer Res. 58: 1893–1900PubMedGoogle Scholar
- Zhu, Q., Zeng, C., Huhalov, A., Yao, J., Turi, T.G., Danley, D., Hynes, T., Cong, Y., DiMattia, D., Kennedy, S., Daumy, G., Schaeffer, E., Marasco, W.A., and Huston, J.S., 1999, Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J. Immunol. Methods 231: 207–22.PubMedCrossRefGoogle Scholar